medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number S1

<< Back Next >>

Ann Hepatol 2009; 8 (S1)

Role of nonalcoholic fatty liver disease in hepatocellular carcinoma

Chávez-Tapia NC, Méndez-Sánchez N, Uribe M

Language: English
References: 62
Page: 34-39
PDF size: 72.99 Kb.


Text Extraction

Obesity and related disorders are a common cause of morbidity worldwide. Nonalcoholic fatty liver disease is the most important hepatic consequence of adipose accumulation. There is strong evidence of obesity-related disorders as risk factors for hepatocellular carcinoma and of nonalcoholic fatty liver disease as a cause of hepatocellular carcinoma, but it is apparently less important than other chronic liver diseases. Unfortunately, preventive measures are not well validated in the population of patients with NAFLD. In this review, we analyze the available information supporting the increased risk of hepatocellular carcinoma in obese patients and patients with nonalcoholic fatty liver disease, considering the epidemiological and basic research-derived evidence.


REFERENCES

  1. Méndez-Sánchez N, Villa AR, Vázquez-Elizondo G, Ponciano-Rodríguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol 2008; 7: 226-9.

  2. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and Survival of Hepatocellular Carcinoma in Turkey: Outcome of Multicenter Study. Jpn J Clin Oncol 2008.

  3. Shibuya K, Yano E. Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972-2001. Int J Epidemiol 2005; 34: 397-402.

  4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-45.

  5. WHO. World Health Statistics 2008. Volume 2008: WHO, 2008.

  6. Yu MC, Yuan JM, Lu SC. Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23 (Suppl 1): S92-7.

  7. Murugavel KG, Naranatt PP, Shankar EM, Mathews S, Raghuram K, Rajasambandam P, Jayanthi V, Surendran R, Murali A, Srinivas U, Palaniswamy KR, Srikumari D, Thyagarajan SP. Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test. J Med Microbiol 2007; 56: 1455-9.

  8. Wong RH, Chen PC, Du CL, Wang JD, Cheng TJ. An increased standardized mortality ratio for liver cancer among polyvinyl chloride workers in Taiwan. Occup Environ Med 2002; 59: 405-9.

  9. Lizardi-Cervera J, Motola-Kuba D, Guevara-González L. [Obesity and its association with cryptogenic cirrhosis and hepatocarcinoma]. Gac Med Mex 2004; 140 Suppl 2: S77-83.

  10. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 846-54.

  11. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will All Americans Become Overweight or Obese? Estimating the Progression and Cost of the US Obesity Epidemic. Obesity (Silver Spring) 2008.

  12. Méndez-Sánchez N, Chávez-Tapia NC, Medina-Santillán R, Villa AR, Sánchez-Lara K, Ponciano-Rodríguez G, Ramos MH, Uribe M. The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis. Dig Dis Sci 2006; 51: 1716-22.

  13. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16: 1087-93.

  14. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.

  15. Lawson DH, Gray JM, McKillop C, Clarke J, Lee FD, Patrick RS. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986; 61: 945-55.

  16. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

  17. Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83: 1820-6.

  18. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997; 73: 204-7.

  19. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.

  20. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.

  21. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-7.

  22. Tazawa J, Maeda M, Nakagawa M, Ohbayashi H, Kusano F, Yamane M, Sakai Y, Suzuki K. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-5.

  23. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.

  24. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-51.

  25. Schiel R, Beltschikow W, Steiner T, Stein G. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006; 28: 169-75.

  26. Evert M, Schneider-Stock R, Dombrowski F. Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest 2005; 85: 99-108.

  27. Lemke L, Rogers A, Nambiar P, Fox J. Obesity and noninsulin dependent diabetes mellitus in Swiss Webster mice associated with late-onset hepatocellular carcinoma. J Endocrinol 2008.

  28. Polesel J, Zucchetto A, Montella M, Maso LD, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2008.

  29. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69-73.

  30. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-5.

  31. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.

  32. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.

  33. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62.

  34. Wang YY, Lin SY. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. Horm Res 2003; 60: 185-90.

  35. Ataseven H, Bahcecioglu IH, Kuzu N, Yalniz M, Celebi S, Erensoy A, Ustundag B. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006; 2006: 78380.

  36. Wang SN, Chuang SC, Yeh YT, Yang SF, Chai CY, Chen WT, Kuo KK, Chen JS, Lee KT. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 2006; 59: 1267-71.

  37. Elinav E, Abd-Elnabi A, Pappo O, Bernstein I, Klein A, Engelhardt D, Rabbani E, Ilan Y. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol 2006; 44: 529-36.

  38. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-91.

  39. Chen C, Chang YC, Liu CL, Liu TP, Chang KJ, Guo IC. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007; 14: 513-29.

  40. Zhou J, Lei W, Shen L, Luo HS, Shen ZX. Primary study of leptin and human hepatocellular carcinoma in vitro. World J Gastroenterol 2008; 14: 2900-4.

  41. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007; 67: 2497-507.

  42. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-103.

  43. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

  44. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005; 33: 72-6.

  45. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54.

  46. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.

  47. Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohwada S, Mori M. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007; 19: 827-34.

  48. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-9.

  49. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, Igari T, Arii S. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 609-14.

  50. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000; 33: 282-9.

  51. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.

  52. Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008; 48: 80-7.

  53. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Miyake S, Enomoto N, Izumi N. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48: 736-42.

  54. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-6.

  55. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-7.

  56. Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008; 8: 200.

  57. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001; 61: 5016-23.

  58. Denda A, Kitayama W, Kishida H, Murata N, Tsutsumi M, Tsujiuchi T, Nakae D, Konishi Y. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 2002; 93: 125-32.

  59. Shiota G. Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor: A NASH animal model. Hepatol Res 2005; 33: 155-60.

  60. Martínez-Chantar ML, Vázquez-Chantada M, Ariz U, Martínez N, Varela M, Luka Z, Capdevila A, Rodríguez J, Aransay AM, Matthiesen R, Yang H, Calvisi DF, Esteller M, Fraga M, Lu SC, Wagner C, Mato JM. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008; 47: 1191-9.

  61. Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, Nakajima T, Miwa S, Murai Y, Hayashi S, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008.

  62. Soga M, Kishimoto Y, Kawamura Y, Inagaki S, Makino S, Saibara T. Spontaneous development of hepatocellular carcinomas in the FLS mice with hereditary fatty liver. Cancer Lett 2003; 196: 43-8.




2020     |     www.medigraphic.com